中部早期青少年市場：依藥品、通路及地區分類

據估計，中東和北非地區的性早熟市場在 2026 年將達到 21.647 億美元，預計到 2033 年將達到 36.854 億美元。預計從 2026 年到 2033 年，該市場將以 7.9% 的複合年成長率成長。

促性腺激素分泌釋放激素 (GnRH)促效劑是治療中樞性性早熟 (CPP) 的潛在選擇，因為它們能抑制內源性 GnRH 的刺激作用並促進骨骼成熟，從而抑制青春期提前。 GnRH 療法可延緩青春期的啟動，並導致初經延遲。曲普瑞林（Tryptodol）、Leuprolide Acetate丙瑞林（Lupron Depot Ped）和Histrelin Acetate瑞林（Suprelin LA）是目前市面上已通過核准用於治療中樞性早熟 (CPP) 的藥物。此外，曲普瑞林、醋酸亮丙瑞林和醋酸組氨瑞林也是促性腺激素釋放激素 (GnRH)促效劑，可根據需要用於延長促性腺激素分泌的抑制時間。作為 GnRH促效劑，曲普瑞林能有效抑制腦下垂體-性腺軸，從而延緩 CPP 兒童的青春期發育。

市場動態

中樞早熟症的治療費用可透過醫療補助計劃 (Medicaid) 報銷，預計這將為全球中樞早熟症市場在預測期內創造良好的成長機會。根據北卡羅來納州醫療補助計劃 (NC Medicaid) 2017 年 12 月發布的公告，用於肌肉注射的緩釋肌注懸浮液Tryptodure 已納入醫療補助計劃的通用醫療程序代碼 (HCPCS) J3490 的報銷範圍。同一資訊來源還指出，自 2017 年 9 月起，北卡羅來納州醫療補助計劃和北卡羅來納州健康選擇計劃 (NCHC) 已將懸浮液納入醫生自主研發藥物計劃 (PDP) 的報銷範圍。向醫療補助計劃和北卡羅來納州健康選擇計劃提交的 Tryptodure 套裝最高報銷金額為 17,280 美元。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
• 本研究根據以下參數介紹了全球中樞性性早熟市場主要參與者的概況：公司概況、財務表現、產品系列、企業發展區域、分銷策略、主要發展和策略以及未來計劃。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
• 這份《全球中樞性性早熟市場》報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用分析全球中心早熟症市場時所使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 產品核准
• 合作關係、併購
• 監理情勢
• PEST分析
• 波特五力分析
• 流行病學
• 穩健的管道分析

第4章 全球中樞神經系統早期青少年藥物市場：依藥物分類，2021-2033年

• Leuprolide Acetate
• 曲普瑞林
• 組氨酸酯
• 納法瑞林

第5章 全球青少年早期消費品市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第6章 全球中青少年早期市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• 熱圖分析
• 市佔率分析
• 公司簡介
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Arbor Pharmaceuticals, LLC
  • Pfizer Inc.
  • Tolmar Pharmaceuticals, Inc.
  • Endo International plc
  • Ipsen Pharma
  • Debiopharm Group
  • Sun Pharmaceutical Industries Limited
• 分析師意見

第8章

• 參考
• 調查方法
• 關於本公司

Central Precocious Puberty Market is estimated to be valued at USD 2,164.7 Mn in 2026 and is expected to reach USD 3,685.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.9% from 2026 to 2033.

Gonadotropin-releasing hormone (GnRH) agonist are potential treatment options for the CPP as they inhibit stimulation effects of endogenous GnRH and accelerate bone maturation, thereby suppressing early puberty. GnRH therapy delays the onset of puberty leading to delay in menarche Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) are approved treatment medications available in the market for central precocious puberty (CPP). Moreover, Triptodur, Lupron Depot-Ped, and Supprelin LA are Gonadotropin-releasing hormone (GnRH) agonists used to prolong the suppression of gonadotropin secretion when required. Triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children with CPP.

Market Dynamics

Reimbursement for the treatment of central precocious puberty is provided through Medicaid, which is expected to offer lucrative growth opportunities for the global central precocious puberty market during the forecast period. According to N.C. Medicaid Bulletin December 2017, Triptodur: an extended-release injectable suspension for intramuscular use, operates under Medicaid Healthcare Common Procedure Coding System (HCPCS) code J3490. According to the same source, from September 2017, N.C. Medicaid and N.C. Health Choice (NCHC) programs cover triptorelin extended-release injectable suspension for intramuscular use (Triptodur) for use in the Physician's Drug Program (PDP). For Medicaid and NCHC billing, the maximum reimbursement rate per unit of Triptodur is: US$ 17,280.00 per kit.

Key features of the study

• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this marke
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global central precocious puberty market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global central precocious puberty market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global central precocious puberty market

Market Segmentation

• By Drug (Revenue, USD Mn, 2021-2033)
• Leuprolide Acetate
• Triptorelin
• Histrelin Acetate
• Nafarelin
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Central Precocious Puberty Market, By Region (Revenue, USD Mn, 2021-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Arbor Pharmaceuticals, LLC
• Pfizer Inc.
• Tolmar Pharmaceuticals, Inc.
• Endo International plc
• Ipsen Pharma
• Debiopharm Group
• Sun Pharmaceutical Industries Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Central Precocious Puberty Market, By Drug, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Leuprolide Acetate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Triptorelin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Histrelin Acetate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Nafarelin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Central Precocious Puberty Market, By Distribution Channel, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Central Precocious Puberty Market, By Region, 2021 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Arbor Pharmaceuticals, LLC
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Tolmar Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Endo International plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Ipsen Pharma
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Debiopharm Group
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Sun Pharmaceutical Industries Limited
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us